Investor Presentaiton

Maxigesic drives international licensing and sales revenue $NZ Millions International total revenue $12.0 $10.0 $8.0 $6.0 $5.9 $4.0 $3.6 $2.0 $0.0 1H $9.9 $9.1 International channel 3% 39% 1H 2021 1H 2022 74% 61% $7.6 97% $4.4 FY2018 FY 2019 FY2020 FY2021 1H FY22 ■ ОТС ■ Hospital • Maxigesic IV licensing income drives strong total revenue growth • Product sales down 35% to $2.6 million as the prior year benefited from stock pipeline fills. • Sales improving as markets move to living with COVID-19. • Royalties more than doubled AFTpharmaceuticals Page 9

View entire presentation